GSK3B and myocardial infarction: We reported that conditional deletion of cardiomyocyte (CM)-GSK-3β protects against myocardial infarction (MI)-induced cardiac remodeling, with no role in Transverse Aortic Constriction (TAC)-induced pathological hypertrophy and cardiac dysfunction [10].